Recent Quotes (30 days)

You have no recent quotes
chg | %

Innovotech Inc  

(Public, CVE:IOT)   Watch this stock  
Find more results for IOT
0.0000 (0.00%)
Delayed:   12:01PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.05
Open     -
Vol / Avg. 0.00/2,001.00
Mkt cap 766,387.00
P/E     -
Div/yield     -
EPS -0.01
Shares 28.74M
Beta -0.01
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -33.35% -35.41%
Operating margin -24.87% -24.30%
EBITD margin - -18.26%
Return on average assets -123.88% -80.59%
Return on average equity - -
Employees 16 -
CDP Score - -


2011-94 Street Suite 101
+1-780-4480585 (Phone)
+1-780-4240941 (Fax)

Website links


Innovotech Inc. provides practical services and solutions for dealing with medical, agricultural and industrial problems caused by microbial biofilms. The Company is engaged in selling of its products, conducting contract research for outside customers, and research and development to identify products for commercialization. Its products include human and veterinary biofilm susceptibility tests, a seed treatment designed to combat both bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. The Company's lead product, InnovoSIL-1, is a silver-based antimicrobial compound that is not inactivated by chloride (salt) that is present in all body tissues. Its products Agress and AgreGuard are used for agricultural applications to high value crops, such as tomatoes. Its biofilm technology consists of the MBEC Assay and Biofilm Eradication Surface Testing (BEST) Assay, which are used for investigating disinfectants and antimicrobial coatings.

Officers and directors

James Timourian Ph.D. Chairman of the Board, President, Chief Financial Officer
Bruce Darryl Hirsche Q.C. Corporate Secretary, Director
Age: 66
Bernard Grobbelaar Director
Robert B. Huizinga Director
Wolfgang H. Muhs Ph.D. Independent Director
Gerard Tertzakian Ph.D. Independent Director